Skip to main content

Primary Hypercholesterolemiia

0
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
Bempedoic acidN/A2 trials
Active Trials
NCT06686615Recruiting2,000Est. Jan 2028
NCT04579367Active Not Recruiting5,000Est. Oct 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Daiichi SankyoBempedoic acid
Daiichi SankyoBempedoic acid

Clinical Trials (2)

Total enrollment: 7,000 patients across 2 trials

NCT06686615Daiichi SankyoBempedoic acid

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Start: Feb 2025Est. completion: Jan 20282,000 patients
N/ARecruiting
NCT04579367Daiichi SankyoBempedoic acid

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

Start: Jan 2021Est. completion: Oct 20265,000 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 7,000 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.